
Daniela Knafelz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4953843/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epidemiological trends of pediatric IBD in Italy: A 10-year analysis of the Italian society of pediatric gastroenterology, hepatology and nutrition registry. Digestive and Liver Disease, 2022, 54, 469-476.	0.9	9
2	Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: A position paper on behalf of the SIGENP IBD working group. Digestive and Liver Disease, 2021, 53, 183-189.	0.9	17
3	Etiology and Management of Pediatric Intestinal Failure: Focus on the Non-Digestive Causes. Nutrients, 2021, 13, 786.	4.1	8
4	Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group. Digestive and Liver Disease, 2021, 53, 283-288.	0.9	14
5	Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn's disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience. Biologics: Targets and Therapy, 2019, Volume 13, 13-21.	3.2	8
6	Use of Biosimilars in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2019, 68, 144-153.	1.8	38
7	Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis. Journal of Pediatric Gastroenterology and Nutrition, 2018, 66, 920-925.	1.8	20
8	Multicentric Case–Control Study on Azathioprine Dose and Pharmacokinetics in Early-onset Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 628-634.	1.9	11
9	Autoimmune liver diseases and inflammatory bowel diseases in children: current issues and future perspectives. Scandinavian Journal of Gastroenterology, 2017, 52, 662-667.	1.5	2
10	Lack of efficacy of infliximab in the treatment of primary sclerosing cholangitis in inflammatory bowel diseases in childhood. European Journal of Gastroenterology and Hepatology, 2017, 29, 736.	1.6	8
11	Pediatric inflammatory bowel disease: specificity of very early onset. Expert Review of Clinical Immunology, 2016, 12, 963-972.	3.0	10
12	Overweight and Pediatric Inflammatory Disease. Journal of Pediatric Gastroenterology and Nutrition, 2015, 61, e10.	1.8	0
13	Transition of gastroenterological patients from paediatric to adult care: A position statement by the Italian Societies of Gastroenterology. Digestive and Liver Disease, 2015, 47, 734-740.	0.9	40
14	The clinical implications of thalidomide in inflammatory bowel diseases. Expert Review of Clinical Immunology, 2015, 11, 699-708.	3.0	16
15	Is Colectomy Still an Option in the Infliximab Era?. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 676-676.	1.8	2
16	Chronic pancreatitis as presentation of Crohn's disease in a child. World Journal of Gastroenterology, 2013, 19, 5204.	3.3	11
17	Plasma Citrulline in Crohn's Disease as a Marker of Inflammation or Disease Localization. Journal of Clinical Gastroenterology, 2012, 46, 622-623.	2.2	3
18	Plasma citrulline as surrogate marker of intestinal inflammation in pediatric and adolescent with Crohn's disease: preliminary report. International Journal of Colorectal Disease, 2011, 26, 1445-1451.	2.2	12

DANIELA KNAFELZ

#	Article	IF	CITATIONS
19	Relationship Between CARD15, SLC22A4/5, and DLG5 Polymorphisms and Early-Onset Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2006, 12, 355-361.	1.9	40
20	Periodic Treatment with Autologous Erythrocytes Loaded with Dexamethasone 21-Phosphate for Fistulizing Pediatric Crohn's Disease. Journal of Pediatric Gastroenterology and Nutrition, 2006, 42, 313-315.	1.8	14
21	Analysis of CARD15 Gene Variants in Italian Pediatric Patients with Inflammatory Bowel Diseases. Journal of Pediatrics, 2005, 147, 272-273.	1.8	13
22	Clinical Outcome And Safety Of Periodic Infliximab Therapy In Children And Adolescents With Crohn's Disease. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, 302-303.	1.8	4
23	Complications of Infliximab Therapy in Children and Adolescents Affected by Crohn's Disease. American Journal of Gastroenterology, 2003, 98, 2812-2813.	0.4	8